{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:07:31Z","timestamp":1792152451724,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eclinm.2026.104120","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:21:43Z","timestamp":1785856903000},"page":"104120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Exploring the rationale for upfront corticosteroid\u2013JAK inhibitor combination therapy in acute severe ulcerative colitis"],"prefix":"10.1016","volume":"98","author":[{"given":"Arshdeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-7758","authenticated-orcid":false,"given":"Arshia","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6961-6389","authenticated-orcid":false,"given":"Ajit","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.eclinm.2026.104120_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrgastro.2016.116","article-title":"Acute severe ulcerative colitis: from pathophysiology to clinical management","volume":"13","author":"Hindryckx","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.104120_bib2","first-page":"1341","article-title":"Animal models of ulcerative colitis and their application in drug research","volume":"7","author":"Low","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104120_bib3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/0016-5085(90)90290-H","article-title":"A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice","volume":"98","author":"Okayasu","year":"1990","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104120_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/gut.2006.094375","article-title":"Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn\u2019s disease","volume":"56","author":"Zeissig","year":"2007","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104120_bib5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104120_bib6","first-page":"1447","article-title":"Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis","volume":"87","author":"Izzo","year":"1992","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104120_bib7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1189\/jlb.0408231","article-title":"The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice","volume":"84","author":"Bento","year":"2008","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.eclinm.2026.104120_bib8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood.V130.Suppl_1.994.994","article-title":"Neutrophil extracellular traps exacerbate inflammatory responses and thrombotic tendency in both a murine colitis model and patients with inflammatory bowel disease","volume":"130","author":"Cao","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104120_bib9","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.immuni.2019.03.017","article-title":"Cytokine networks in the pathophysiology of inflammatory bowel disease","volume":"50","author":"Friedrich","year":"2019","journal-title":"Immunity"},{"issue":"33","key":"10.1016\/j.eclinm.2026.104120_bib10","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.3748\/wjg.14.5110","article-title":"Role of STAT3 in inflammatory bowel disease","volume":"14","author":"Sugimoto","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104120_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41423-019-0315-0","article-title":"Epigenetic regulation of macrophages: from homeostasis maintenance to host defense","volume":"17","author":"Chen","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104120_bib12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/1744666X.2023.2214728","article-title":"The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease","volume":"19","author":"Gupta","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.eclinm.2026.104120_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s43556-023-00151-1","article-title":"JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions","volume":"4","author":"Sarapultsev","year":"2023","journal-title":"Mol Biomed"},{"issue":"9857","key":"10.1016\/j.eclinm.2026.104120_bib14","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104120_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Supplement_1","key":"10.1016\/j.eclinm.2026.104120_bib16","doi-asserted-by":"crossref","first-page":"i812","DOI":"10.1093\/ecco-jcc\/jjac190.0811","article-title":"P681 effectiveness and safety of oral tacrolimus salvage therapy for acute severe ulcerative colitis: a retrospective study","volume":"17","author":"Tamir-Degabli","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.eclinm.2026.104120_bib17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s12876-021-02043-6","article-title":"Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus","volume":"21","author":"Shimizu","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104120_bib18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/gut.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.eclinm.2026.104120_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2024-332489","article-title":"Acute severe ulcerative colitis trials: the past, the present and the future","author":"Honap","year":"2024","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104120_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","article-title":"Acute severe ulcerative colitis management: unanswered questions and latest insights","volume":"9","author":"Rivi\u00e8re","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104120_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf161","article-title":"Combination therapy with biologics and\/or small molecules in inflammatory bowel disease: a comprehensive review","volume":"19","author":"Gisbert","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104120_bib22","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/s41385-018-0050-3","article-title":"The current state of the art for biological therapies and new small molecules in inflammatory bowel disease","volume":"11","author":"Paramsothy","year":"2018","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.eclinm.2026.104120_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1442519","article-title":"Corticosteroids combined with infliximab vs. corticosteroids sequential infliximab for acute severe ulcerative colitis with mucosal deficiency: a retrospective study","volume":"11","author":"Liu","year":"2024","journal-title":"Front Med"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104120_bib24","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.104120_bib25","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience","author":"Berinstein","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104120_bib26","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104120_bib27","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cgh.2018.11.022","article-title":"Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis","volume":"17","author":"Berinstein","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104120_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/2050640620977405","article-title":"Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: a multicentre cohort study","volume":"9","author":"Festa","year":"2021","journal-title":"United European Gastroenterol J"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104120_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/gutjnl-2024-333281","article-title":"Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial","volume":"74","author":"Amiot","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.eclinm.2026.104120_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/apt.70246","article-title":"Azathioprine or tofacitinib as maintenance therapy in corticosteroid-responsive acute severe ulcerative colitis","author":"Singh","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104120_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cyto.2009.08.002","article-title":"Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination","volume":"48","author":"Huang","year":"2009","journal-title":"Cytokine"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:27:16Z","timestamp":1787560036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026003731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S2589537026003731"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104120","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the rationale for upfront corticosteroid\u2013JAK inhibitor combination therapy in acute severe ulcerative colitis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104120"}}